Aanjaneya Lifecare’s board of directors have approved the issue of securities/Foreign Currency Convertible Bonds to the tune of $75 million to Qualified Institutional Buyers (QIBs), which is yet to be identified by the investment committee of the company, through Qualified Institutional Placement (QIP) in tranches over a period of 18 months out of which first tranche would aggregate to $25 million to be allocated for ongoing capital expenditure and potential acquisitions.
The company in the same meeting held on April 02,2012, decided to appoint merchant bankers to oversee the above referred process and further to undertake all such steps and to appoint such other agencies in this regard.
Aanjaneya Lifecare is a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities. It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: